| 摘要 |
Disclosed is a pharmaceutical formulation which comprises: (1) azelastine, or a pharmaceutically acceptable salt thereof (such as azelastine hydrochloride); and (2) in an amount from 50 micrograms/ml to 5 mg/ml of the formulation, (a) fluticasone or a pharmaceutically acceptable ester thereof, provided that the pharmaceutically acceptable ester is not fluticasone propionate or fluticasone valerate, (b) mometasone or a pharmaceutically acceptable ester thereof, provided that the pharmaceutically acceptable ester is not mometasone furoate or mometasone furoate monohydrate, or (c) ciclesonide. The preferred formulations are in a form suitable for nasal or ocular administration. (62) Divided Out of 560480 |
